Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1498)	5/21/2004 10:22:16 AM
From: seminole	Read Replies (1) \| Respond to of 1826

The slides from the BofA presentation are on the Home Page. The weekly Aloxi sales are shown in slide #10 and Iro prostate results are shown in slide 21. veracast.com

To: Icebrg who wrote (1498)	6/11/2004 3:54:14 PM
From: Icebrg	Read Replies (1) \| Respond to of 1826

MGI Pharma "outperform" Friday, June 11, 2004 7:12:27 AM ET Robert W. Baird NEW YORK, June 11 (New Ratings) - Analysts at Robert W Baird maintain their "outperform" rating on MGI Pharma (MOGN.NAS). The target price is set to $35. [Outperform going from 32 to 35? I suppose he sees the rest of the biotech sector in a free fall for the rest of the year]. In a research note published yesterday, the analysts mention that the company's share price depreciated by 7% yesterday due to the misinterpretation of an article published in the New England Journal of Medicine (NEJM). The article details the use of anti-emetics for the treatment of Post-Operative Nausea and Vomittng (PONV), the analysts say. The analysts mention, however, that the company's PONV-related products are not factored in the estimates and that the current weakness in MGI Pharma’s share price provides an attractive buying opportunity.